key: cord-0814961-03kscxfh
authors: Roque, Marylin; Proudfoot, Kevin; Mathys, Vadim; Yu, Sophie; Krieger, Natalie; Gernon, Thomas; Gokli, Kash; Hamilton, Stanley; Cook, Colin; Fong, Yuman
title: A review of nasopharyngeal swab and saliva tests for SARS‐CoV‐2 infection: Disease timelines, relative sensitivities, and test optimization
date: 2021-06-06
journal: J Surg Oncol
DOI: 10.1002/jso.26561
sha: 7b0462aac8417cccefd689480f33350b2390f474
doc_id: 814961
cord_uid: 03kscxfh

Testing is an essential part of containment of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) pandemic. This review summarizes studies for SARS‐CoV‐2 infection and testing. Nasopharyngeal samples are best at sensitivity detection, especially in early stages of disease and in asymptomatic individuals. Current swab processing involves a 100‐ to 1000‐fold dilution of the patient sample. Future optimization of testing should focus on using smaller volumes of viral transport media and swab designs to increase comfort and increased viral adhesion.

SARS-CoV-2 belongs to the coronavirus family, which are enveloped, positive-sense, single-stranded RNA viruses. The SARS-CoV-2 virus possesses unique features that allow it to bind and infect human cells. A notable feature, essential to viral function, is the spike protein protruding from the envelope of the novel coronavirus. 4 Within the spike protein is a receptor-binding domain that helps facilitate a connection to the cellular receptor angiotensin-converting enzyme 2 (ACE2) on human cells. After contact with a human host cell, enzymes such as TMPRSS2 break the spike protein at one or more cleavage sites, exposing fusion peptides that fuse the viral membrane with the cell membrane. This effectively creates a bridge for the viral RNA to enter and replicate within host cells. Cells with ACE2 expression include but are not limited to the ciliated epithelium in the nasal cavity (not including the anterior portion), ciliated epithelium in the paranasal sinuses, oral cells in the minor salivary glands, and ciliated airway epithelial cells in the lung. 6, 7 The earliest infection is known to occur in the nasal passage, an area where a recent study found ACE2 expression in 20% of the cells. 7 The percentage of ciliated cells expressing ACE2 decreases along the respiratory tract. 7 The expression of ACE2 receptors in the bronchi is roughly one-half of that in the nasopharynx. 7 This lower percentage of cells with ACE2 expression is the reason for a lower rate of infection within the distal airways.

In most respiratory cells, cilia are another factor in infection.

Normally cilia beat synchronously, performing mucociliary clearance (MCC), an innate defense mechanism that removes unwanted particles and bacteria from the respiratory system. Synchronously beating cilia propel mucus from the distal airways to the nasopharynx and from the nasal cavity and paranasal sinuses towards the oropharynx. 8 Current knowledge of viral progression supports a theory of infection on the MCC system from proximal to distal airways. 9 Starting in the nasal passage or oral cavity, the infection may then proceed into the lower respiratory system through oral-lung aspiration. For around 80% of patients, the disease will remain mild and be contained within the upper airways. 10 Studies indicate that nasal secretions are swept from the nasal surface by MCC to accumulate in the oral cavity at a rate of ∼0.5 ml/h. 7 From there, small volumes of high titer (concentrated) virus are aspirated into the deep lung, causing more severe infections.

The timeline of infection and list of common coronavirus symptoms provided in research studies and CDC guidelines align with this theory of infection ( Figure 1 ). The median time from infection to symptom onset was reported to be 5 days (range of 2-14 days). 11 According to the theory of infection, viral particles replicate within the nasal and oral cavities during this presymptomatic period. In the 10 days following symptom onset, the patient will exhibit a variety of symptoms including but not limited to fever, cough, sore throat, runny nose, loss of taste or smell, and fatigue. 12 These symptoms align with the progression of infection from proximal to distal airways.

Previous studies of SARS-CoV, as well as more recent studies of SARS-CoV-2, determined that coronavirus infections cause the destruction or loss of cilia in ciliated cells. 13 Initial infection of the nasal passage leads to the cytopathic destruction of nasal epithelial cells responsible for nasal MCC, 9 symptomatic as a runny nose. There may also be an infection of sustentacular or supporting olfactory epithelial cells which can cause anosmia (loss of smell). These two commonly observed initial COVID-19 symptoms support a model of infection beginning in the nasal passage.

The second major entry point of the virus is the stratified squamous epithelium of the oropharynx and laryngopharynx, causing laryngitis (inflammation of the voice box) and pharyngitis (inflammation of the throat). These inflammations lead to symptoms of sore throat and hoarseness of voice. Another notable infection is that of taste bud epithelial cells, which causes ageusia (loss of taste). 9 From there, serious infections proceed through the respiratory tract, infecting areas of the trachea, bronchi, bronchiole, and alveoli, in that order. Normally, inhaled particles of pathogens are eliminated in about 20 min from the end of the large bronchi to the pharynx. 9 However, due to the loss of cilia, this process is disrupted. As the infection progresses, MCC slows and more cells are infected.

Depending on the viral load and the host immune response, the progression through the lower airways may be rapid (1-2 days) or slow (7-14 days). 9 Around 10-12 days after initial symptoms, the patient can develop acute respiratory distress syndrome (ARDS) and require hospitalization. 11, 14 This more severe reaction indicates that the virus has moved into the distal airways and has most likely infected the alveoli. 9 Understanding this timeline of infection and theorized progression of the virus is essential in developing tests and treatments for SARS-CoV-2. Tests that allow early diagnosis during the presymptomatic period allow for isolation of patients to prevent spread of disease and early treatments for best outcomes.

Numerous testing methods have been developed or adapted for detecting SARS-CoV-2 since the beginning of the pandemic. There are three main forms of tests (Table 1) . A molecular test detects viral genetic material. An antigen test detects specific viral proteins to determine if the patient is currently infected. Finally, an antibody test detects antibodies to SARS-CoV-2 and determines whether someone has been previously infected. This review will focus on the sampling methods for molecular and antigen tests. The most effective and common testing methods focus on one of the following three anatomic areas: the nasal cavity (specifically the nasopharynx), the oral cavity and pharynx, or the lower respiratory system (lungs). The most common ways to test these areas are to use a swab, collect saliva, or collect sputum. While different studies may report different sensitivity values, there is a relatively strong consensus regarding the effectiveness of each testing method. F I G U R E 2 (A) Sample processing and associated dilution factors. Based on these values, a 50-100 μl swab sample undergoes an overall dilution of anywhere from 120-to 1500-fold, the majority occurring when the patient sample is placed into the viral transport medium (VTM) for transport from testing site to laboratory. (B) Viral load as a function of volume collected by a swab. The volume of VTM the swab was placed into has a great influence on the required viral load, as Allplex (3 ml) requires anywhere from 2×10 5 to 6×10 6 viral copies/ml in nasal secretions for detection. Allplex (300 μl) requires 2×10 4 to 3×10 5 viral copies/ml in nasal secretions for detection. All lines represent the sample processing conditions used by the authors this paper reviews (see Table S1 ). Allplex (3 ml) is shown as a range, rather than a single line, as RNA extraction methods were unspecified by the authors [Color figure can be viewed at wileyonlinelibrary.com] here. Using dilution factors associated with the assays (Table 1) , an elution efficiency of 31.3%, 24 and assuming three viral genomes per reaction to start with (Poisson Distribution − 95% chance of having at least one viral genome copy to amplify in the PCR), the Allplex Assay has the lowest LoD ( Figure 2B ). Note that it is the dilution of the starting sample into different volumes of VTM that drives the difference in LoD. The Allplex assay uses only 300 μl VTM, compared to 3000 μl in other assays. 3 and 4) .

In the first few days of infection, SARS-CoV-2 symptoms are similar to those of other respiratory pathogens. For example, fever, cough, and runny nose are symptoms of both influenza and SARS-CoV-2 infection. 28 To distinguish SARS-CoV-2 from other respiratory pathogens early in the infection, the diagnosis can be made using multiplex respiratory panels (MRP). MRP are assays that can identify and differentiate between multiple respiratory pathogens. Two such MRP are the Luminex xTAG Respiratory Viral Panels and the BioFire Diagnostics FilmArray Respiratory Panel, each of which can detect 20+ pathogens. They typically have varying limits of detection for each pathogen. For example, the BioFire RP has an LoD of 3.0×10 3 copies/ml for adenovirus, which is on par with the LoD for some of the more restrictive SARS CoV-2 assays (Table S1 ). While the specificity, sensitivity, and cross-reactivity must be taken into consideration, using a MRP can help public health experts quickly determine which patients are infected with SARS-CoV-2, and which are infected with other respiratory pathogens. From a practical standpoint, patients with respiratory symptoms are likely to have symptoms like the flu and be tested by a respiratory pathogen panel. The viral load is shown in log10 RNA copies/ml. Different papers expressed viral load in different units, most commonly in C t and RNA copies/ml. Converting to log 10 RNA copies/ml from RNA copies/ml was done using the log 10 function. Converting to log 10 RNA copies/ml from C t was done using the linear relationship presented in Vogels et al. 26 Data on viral load was then binned into days: incubation (Days 0-5), viral shedding (Days 6-7), symptomatic (Days [8] [9] [10] [11] [12] [13] [14] , and recovery (Days 15+) since this is a common breakdown for COVID-19. 27 All tabulated values used to make this figure can be found in Table S2 [Color figure can be viewed at wileyonlinelibrary.com] These values were converted to log 10 RNA copies/ml, using methods of Vogels et al. 26 to convert from C t . Full tabulated values used to make this figure can be found in Table S2 [ 

Of the studies reviewed, four included information on asymptomatic and presymptomatic cases. Two studies reported that there was no statistically significant difference in viral load between asymptomatic and symptomatic cases. 29 As shown in Figure 3 , there is a very wide range in viral load across COVID-19 cases. This is confirmed by multiple studies that were reviewed, most notably by Arnaout et al. who reported viral load in COVID-19 cases to be evenly distributed between 2.5 and 8.5 log 10 copies/ml. 33 In symptomatic patients, this wide range can be explained by the theory of infection as cases with more severe symptoms have a viral load of 10 vg/ml for longer than those with less severe symptoms, though both severe and mild cases are included in the symptomatic grouping. 34 Asymptomatic patients have, on average, a lower viral load of 4.05e7 vg/ml at the peak loading compared to 1.12e8 vg/ml in symptomatic patients. Asymptomatic patients also test negative earlier than symptomatic patients-on average asymptomatic patients first test negative 16 days after presumed infection while symptomatic patients first test negative 21 days after presumed infection ( Figure 3) . However, since the range of symptomatic case viral load encompasses the range for asymptomatic cases, testing methods and protocols that are used on symptomatic cases will also capture asymptomatic cases. The most worrisome conclusion from these data is that asymptomatic patients can still be infectious for many days. Finding these patients, who are mobile and don't appear to be ill, must be a goal of any public health screening program to slow the spread of disease and stop the pandemic. Based on Figure 4A , NP swabs carry, on average, a higher viral load than saliva. NP swabs collect an average of 3.02e7 vg/ml during peak viral load (Days 0-5) whereas saliva tests collect an average of 5.16e5 vg/ml during peak viral load (Days 6-7). However, the difference between NP swabs and saliva tests may not matter depending on the LoD of the assay being used. For an LoD of 80 copies/ml (lowest reported in this paper, see Figure 4A also supports that an NP swab is more likely to carry a higher viral load and therefore be more likely to test positive than a saliva test.

Perhaps a more important distinction between NP swabs and saliva tests is their ability to detect SARS-CoV-2 early in a patient's infection. Figure 4B shows a magnified image of Figure 

Accurately detecting the virus at an early stage can deter further spread, help prevent deaths, and reduce economic burden. Figure 5 shows the economic burden of different testing and sheltering scenarios. The left branch of the tree in Figure 5 , highlighted in red, The right branch of Figure 5 , highlighted in green, projects a more ideal case where testing has an improved FNR of 5%. Using this new FNR with the same assumptions for sheltered and unsheltered individuals yields a much lower economic burden, as can be observed in the bottom row of boxes in Figure 5 . This comparison demonstrates the importance of developing tests that can accurately detect the virus as there is immense value in ensuring that infected individuals are aware of their situation and do their best to mitigate spread.

The COVID-19 pathophysiology and time course suggest that most infected individuals do not experience serious symptoms in the first

week after infection with SARS-CoV-2. However, these infected people also have the highest level of viral shedding around Day 5 after exposure. 39 The ease with which unknown community spread occurs has been a significant challenge that governments and communities have faced in controlling the spread of SARS-CoV-2. This problem is only exacerbated by long incubation periods and asymptomatic cases.

One method to increase the sensitivity of tests and thus decrease the FNR is to focus on the volume of VTM used in assays.

Currently, CDC guidelines recommend using 2-3 ml of VTM per sample. 40 Unfortunately, the usage of VTM introduces a dilution factor that may severely impact the effectiveness of assays. For example, if the average NP swab collects and releases 50 μl of nasal secretions and is stored in a tube of 3 ml VTM, the original sample would be diluted 60:1 (Figure 2A) . Such a large dilution factor can be the difference between a positive and a false-negative result by F I G U R E 5 Potential testing scenarios and their associated costs calculated for a population of 100,000 (assuming that the entire population is tested). A lower false-negative rate along with individuals who shelter at home leads to the lowest economic burden, whereas a higher falsenegative rate with individuals who do not shelter at home leads to the highest economic burden. This analysis highlights why the false-negative rate is the salient metric when comparing test efficacy. The majority of the economic burden comes from asymptomatic patients not being detected and quarantined to break the chain of infection (type II error). The personal and societal costs of false-negative rate (FNR) are significant [Color figure can be viewed at wileyonlinelibrary.com] pushing a sample below the LoD. As seen in Figure 2B with the Allplex example, a 10-fold difference in VTM volume to 300 µl can drastically change the number of viral copies required for detection.

Few published sources justify the need for 2-3 ml of VTM per sample. On ResearchGate, it was claimed that some laboratories require 3 ml of the sample to be centrifuged at low RPMs for sedimenting heavy debris. 41 Furthermore, assay manuals, such as the The need for placing the current sampling swabs in each nostril for prolonged periods has been an obstacle for compliance to testing.

Comfort may be increased by designing an NP swab with more surface area on the tip and made out of a material that binds to the virus better than currently used materials, such that the swab requires less time inside of the patient's nose. The redesigned swab should meet or exceed current NP performance in the collection of patient samples, comfort, and required insertion time.

The authors would like to acknowledge and thank several individuals whose contributions have made this paper possible. The authors thank 

Coronavirus World Map: Tracking the Global Outbreak

Coronavirus disease (COVID-19): World Health Organization

Profile of a killer: the complex biology powering the coronavirus pandemic

SARS-CoV-2 and COVID-19 Pathogenesis: A Review

COVID-19: A risk assessment perspective

Sars-CoV-2 reverse genetics reveals a variable infection gradient in the respiratory tra

A pathophysiological model for COVID-19: critical importance of transepithelial sodium transport upon airway infection

Pathogenesis of COVID-19 from a cell biology perspective

Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection

Duration of Isolation and Precautions for Adults with COVID-19: Centers for Disease Control

COVID-19, cilia, and smell

A Timeline of COVID-19 Symptoms: Blue Cross and Blue Shield of North Carolina

Usual Weekly Earnings of Wage and Salary Workers

Estimating the overdispersion in COVID-19 transmission using outbreak sizes outside China

Changing Metrics and Additional Resources

United States COVID-19 Cases and Deaths by State over Time: Centers for Disease Control and Prevention

COVID-19) testing: What you should know

Sensitivity of nasopharyngeal swabs and saliva for the detection of severe acute respiratory syndrome coronavirus 2

Swabs collected by patients or health care workers for SARS-CoV-2 testing

Detection of SARS-CoV-2 in Different Types of Clinical Specimens

BAL): National Library of Medicine

The extraction and recovery efficiency of pure DNA for different types of swabs

The influence of a swab type on the results of pointof-care tests

Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets

Viral cultures for COVID-19 infectivity assessment. medRxiv

Similarities and differences between flu and COVID-19

Clinical course and molecular viral shedding among asymptomatic and symptomatic patients with SARS-CoV-2 infection in a community treatment center in the Republic of Korea

Upper respiratory viral load in asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2 infection

The natural history and transmission potential of asymptomatic severe acute respiratory syndrome coronavirus 2 infection

Repeat COVID-19 molecular testing: correlation of SARS-CoV-2 culture with molecular assays and cycle thresholds

SARS-CoV2 testing: the limit of detection matters

Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study

Saliva or nasopharyngeal swab specimens for detection of SARS-CoV-2

Saliva sample as a non-invasive specimen for the diagnosis of coronavirus disease 2019: a cross-sectional study

The potential health care costs and resource use associated with COVID-19 In the United States. Health Aff

Transmission of COVID-19: European Centre for Disease Prevention and Control

Virological assessment of hospitalized patients with COVID-2019

Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-19: Centers for Disease Control and Prevention

Does the reduction of volume of the viral transport medium (VTM) during sampling increase the concentration of viral load in the sample?

A review of nasopharyngeal swab and saliva tests for SARS-CoV-2 infection: Disease timelines, relative sensitivities, and test optimization

The authors declare that there are no conflict of interests.

All data have been presented in the manuscript.

http://orcid.org/0000-0002-8934-9959